International Group Structuring for Pharmaceutical Chain

A major pharmaceutical chain operating across the CIS and the UAE was running intercompany flows between group entities in two very different legal environments. Cross-border contractual arrangements between UAE and CIS companies carried exposure on multiple fronts: substance of intragroup transactions, allocation of IP and marketing functions, and consistency of the paper trail across jurisdictions. The client needed a clean contractual backbone that would hold up to scrutiny from tax authorities and counterparties on both sides — before scaling further activity through the group.

We structured the group's intercompany framework end-to-end, aligning contracts with the actual flow of value between the UAE and CIS entities:

1. Cross-border review — analyzed existing contractual schemes between UAE and CIS companies inside the group, mapped intercompany flows, and identified weak points in how functions and risks were allocated.
2. License agreements — drafted intragroup license agreements covering the rights used across the chain, with terms aligned to the group's operating model in both regions.
3. Marketing services agreements — prepared marketing services contracts between group entities, calibrating scope, deliverables, and pricing logic for cross-border use.
4. Documentation package — assembled a consistent set of templates and supporting documents so future transactions inside the group follow the same contractual logic.